Use of compound or medicinal derivative thereof in inhibiting AIM2 protein activity
US11944603B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jun 10, 2022 |
| Grant date | Apr 2, 2024 |
| Priority date | — |
| Expiry date | Jun 10, 2042 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A use of a compound or a medicinal derivative thereof in inhibiting absent in melanoma 2 (AIM2) protein activity is provided, and belongs to the field of protein inhibitory medicine technology. Compared with traditional broad-spectrum immunomodulators, the compound has a strong targeting effect, and is more accurate, rapid, effective, safe and stable. Moreover, the compound has a strong binding force with human AIM2 protein and mouse AIM2 protein, and binding constants are as high as 1.029E-5M and 1.033E-5M respectively. Compared with traditional biological inhibitors, the compound has advantages of easy storage, stable activity, small molecular weight, lower production cost and easy absorption.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.